"People still think #lungcancer has a type. It doesn't. Anyone with lungs can get it."
Lung Cancer Awareness Month starts tomorrow. Our President Debra Montague on the conversations Europe needs to start, and why stigma keeps getting in the way.
lungcancereurope.eu/news/lung-ca... #LCSM
Lung Cancer Awareness Month starts tomorrow. Our President Debra Montague on the conversations Europe needs to start, and why stigma keeps getting in the way.
lungcancereurope.eu/news/lung-ca... #LCSM
October 31, 2026 at 8:28 AM
"People still think #lungcancer has a type. It doesn't. Anyone with lungs can get it."
Lung Cancer Awareness Month starts tomorrow. Our President Debra Montague on the conversations Europe needs to start, and why stigma keeps getting in the way.
lungcancereurope.eu/news/lung-ca... #LCSM
Lung Cancer Awareness Month starts tomorrow. Our President Debra Montague on the conversations Europe needs to start, and why stigma keeps getting in the way.
lungcancereurope.eu/news/lung-ca... #LCSM
Why are people who have never smoked excluded from routine #lungcancer screening?
New research from Singapore examines whether family history and individual risk could help identify people who might benefit.
Could screening look beyond smoking history? #LCSM
doi.org/10.1186/s129...
New research from Singapore examines whether family history and individual risk could help identify people who might benefit.
Could screening look beyond smoking history? #LCSM
doi.org/10.1186/s129...
October 30, 2026 at 4:06 PM
Why are people who have never smoked excluded from routine #lungcancer screening?
New research from Singapore examines whether family history and individual risk could help identify people who might benefit.
Could screening look beyond smoking history? #LCSM
doi.org/10.1186/s129...
New research from Singapore examines whether family history and individual risk could help identify people who might benefit.
Could screening look beyond smoking history? #LCSM
doi.org/10.1186/s129...
Get Checked! 2026 launches today 🧡
Lung cancer. Two sides to every diagnosis.
This November, for #LungCancerAwarenessMonth, Lung Cancer Europe is focusing on primary care, with stories from people living with lung cancer and the teams who diagnose it.
Explore the campaign 👉 getchecked.eu
#LCSM
Lung cancer. Two sides to every diagnosis.
This November, for #LungCancerAwarenessMonth, Lung Cancer Europe is focusing on primary care, with stories from people living with lung cancer and the teams who diagnose it.
Explore the campaign 👉 getchecked.eu
#LCSM
Get Checked! by Lung Cancer Europe | Lung Cancer Awareness
Lung Cancer Europe's Get Checked! 2026: real stories from people with lung cancer and the healthcare professionals on both sides of diagnosis.
getchecked.eu
November 1, 2026 at 4:31 PM
Get Checked! 2026 launches today 🧡
Lung cancer. Two sides to every diagnosis.
This November, for #LungCancerAwarenessMonth, Lung Cancer Europe is focusing on primary care, with stories from people living with lung cancer and the teams who diagnose it.
Explore the campaign 👉 getchecked.eu
#LCSM
Lung cancer. Two sides to every diagnosis.
This November, for #LungCancerAwarenessMonth, Lung Cancer Europe is focusing on primary care, with stories from people living with lung cancer and the teams who diagnose it.
Explore the campaign 👉 getchecked.eu
#LCSM
Thoracic oncologists discuss HER2 testing, frontline treatment selection, and resistance mechanisms in HER2-altered non–small cell lung cancer. @pateloncology.bsky.social @mskcancercenter.bsky.social @ucsdcancer.bsky.social @gustaveroussy.fr #lcsm #oncology
www.onclive.com/view/broaden...
www.onclive.com/view/broaden...
Broadening HER2-Mutated NSCLC Data Support First-Line Zongertinib Followed by T-DXd | OncLive
Thoracic oncologists discuss HER2 testing, frontline treatment selection, and resistance mechanisms in HER2-altered non–small cell lung cancer.
www.onclive.com
October 30, 2026 at 2:32 AM
Thoracic oncologists discuss HER2 testing, frontline treatment selection, and resistance mechanisms in HER2-altered non–small cell lung cancer. @pateloncology.bsky.social @mskcancercenter.bsky.social @ucsdcancer.bsky.social @gustaveroussy.fr #lcsm #oncology
www.onclive.com/view/broaden...
www.onclive.com/view/broaden...
New #ESMO26 real-world data from Japan: in 720 people with ALK+ #LungCancer who had alectinib as their first ALK inhibitor, median overall survival was 103.3 months, around 8.6 years. For those with brain metastases when starting treatment, it was 80 months.
#LCSM
#LCSM
October 27, 2026 at 9:18 PM
New #ESMO26 real-world data from Japan: in 720 people with ALK+ #LungCancer who had alectinib as their first ALK inhibitor, median overall survival was 103.3 months, around 8.6 years. For those with brain metastases when starting treatment, it was 80 months.
#LCSM
#LCSM
The EA5221/ACHIEVE clinical study is testing two different treatment approaches for older adults with advanced non-small cell #LungCancer. Learn more: https://bit.ly/ea5221-achieve #NSCLC #LCSM
October 27, 2026 at 2:00 PM
The EA5221/ACHIEVE clinical study is testing two different treatment approaches for older adults with advanced non-small cell #LungCancer. Learn more: https://bit.ly/ea5221-achieve #NSCLC #LCSM
Sunday begins Lung Cancer Awareness Month - will you take the challenge to raise awareness of #LungCancer, help improve screening rates, and reduce the stigma around the disease? LCRF will post a new challenge each week in November - so watch this space to get involved! #LCAM #LCSM
October 26, 2026 at 6:53 PM
Sunday begins Lung Cancer Awareness Month - will you take the challenge to raise awareness of #LungCancer, help improve screening rates, and reduce the stigma around the disease? LCRF will post a new challenge each week in November - so watch this space to get involved! #LCAM #LCSM
📅 Register now!
The 25th BTOG Annual Conference takes place 3–5 March 2026 at the EICC Edinburgh. Join the UK’s leading thoracic oncology community.
🔗 https://btog.org/25th-btog-annual-conference-2027
#LCSM
The 25th BTOG Annual Conference takes place 3–5 March 2026 at the EICC Edinburgh. Join the UK’s leading thoracic oncology community.
🔗 https://btog.org/25th-btog-annual-conference-2027
#LCSM
October 27, 2026 at 7:00 AM
📅 Register now!
The 25th BTOG Annual Conference takes place 3–5 March 2026 at the EICC Edinburgh. Join the UK’s leading thoracic oncology community.
🔗 https://btog.org/25th-btog-annual-conference-2027
#LCSM
The 25th BTOG Annual Conference takes place 3–5 March 2026 at the EICC Edinburgh. Join the UK’s leading thoracic oncology community.
🔗 https://btog.org/25th-btog-annual-conference-2027
#LCSM
sac-TMT plus pembrolizumab improved PFS in the first-line treatment of PD-L1–negative, advanced nonsquamous NSCLC without EGFR or ALK alterations in the phase 3 OptiTROP-Lung06 trial #ESMO26 #lcsm #oncology
Read more: www.onclive.com/view/sacituz...
Read more: www.onclive.com/view/sacituz...
October 28, 2026 at 3:20 PM
sac-TMT plus pembrolizumab improved PFS in the first-line treatment of PD-L1–negative, advanced nonsquamous NSCLC without EGFR or ALK alterations in the phase 3 OptiTROP-Lung06 trial #ESMO26 #lcsm #oncology
Read more: www.onclive.com/view/sacituz...
Read more: www.onclive.com/view/sacituz...
EU and Japan applications are seeking the approval of savolitinib plus osimertinib for the treatment with advanced/metastatic EGFR-mutated NSCLC with MET overexpression or amplification whose disease progressed on or after an EGFR TKI #lcsm #oncology
Red more: www.onclive.com/view/eu-japa...
Red more: www.onclive.com/view/eu-japa...
EU, Japanese Approval Is Sought for Savolitinib Plus Osimertinib in MET-Driven EGFR-Mutated NSCLC | OncLive
Phase 3 SAFFRON data support EU and Japanese filings for savolitinib plus osimertinib in EGFR-mutated NSCLC with MET overexpression or amplification.
www.onclive.com
November 2, 2026 at 6:24 PM
EU and Japan applications are seeking the approval of savolitinib plus osimertinib for the treatment with advanced/metastatic EGFR-mutated NSCLC with MET overexpression or amplification whose disease progressed on or after an EGFR TKI #lcsm #oncology
Red more: www.onclive.com/view/eu-japa...
Red more: www.onclive.com/view/eu-japa...
The eight-year ADAURA results raise a big question: are we curing more patients with resected EGFR-mutated lung cancer, or delaying relapse?
Tom Newsom-Davis & Riyaz Shah discuss the long-term data.
https://btog.org/btog-wclc-update-webinar/
#lcsm
Tom Newsom-Davis & Riyaz Shah discuss the long-term data.
https://btog.org/btog-wclc-update-webinar/
#lcsm
October 28, 2026 at 1:00 PM
The eight-year ADAURA results raise a big question: are we curing more patients with resected EGFR-mutated lung cancer, or delaying relapse?
Tom Newsom-Davis & Riyaz Shah discuss the long-term data.
https://btog.org/btog-wclc-update-webinar/
#lcsm
Tom Newsom-Davis & Riyaz Shah discuss the long-term data.
https://btog.org/btog-wclc-update-webinar/
#lcsm
In phase 3 SANOVO, savolitinib + osimertinib (Tagrisso) extended median PFS to 24.9 months vs 13.8 months with osimertinib alone in the overall study population.
@myesmo.bsky.social #ESMO36 #lcsm
🔗 Read more: www.onclive.com/view/savolit...
@myesmo.bsky.social #ESMO36 #lcsm
🔗 Read more: www.onclive.com/view/savolit...
October 27, 2026 at 12:45 AM
In phase 3 SANOVO, savolitinib + osimertinib (Tagrisso) extended median PFS to 24.9 months vs 13.8 months with osimertinib alone in the overall study population.
@myesmo.bsky.social #ESMO36 #lcsm
🔗 Read more: www.onclive.com/view/savolit...
@myesmo.bsky.social #ESMO36 #lcsm
🔗 Read more: www.onclive.com/view/savolit...
Big ESMO 2026 news for extensive-stage small cell #lungcancer: phase III DeLLphi-305 shows tarlatamab + durvalumab extended median survival to 21.1 vs 12.7 months on durvalumab alone. 58% lower risk of death.
Both drugs already exist in Europe. Access is the next fight. #LCSM
Both drugs already exist in Europe. Access is the next fight. #LCSM
October 24, 2026 at 2:51 PM
Big ESMO 2026 news for extensive-stage small cell #lungcancer: phase III DeLLphi-305 shows tarlatamab + durvalumab extended median survival to 21.1 vs 12.7 months on durvalumab alone. 58% lower risk of death.
Both drugs already exist in Europe. Access is the next fight. #LCSM
Both drugs already exist in Europe. Access is the next fight. #LCSM
Extended follow-up data from DeLLphi-304 showed tarlatamab sustained survival benefits in patients with SCLC whose disease progressed during or after first-line platinum-based therapy #ESMO26 #lcsm #oncology
Read more: www.onclive.com/view/extende...
Read more: www.onclive.com/view/extende...
October 26, 2026 at 8:26 PM
Extended follow-up data from DeLLphi-304 showed tarlatamab sustained survival benefits in patients with SCLC whose disease progressed during or after first-line platinum-based therapy #ESMO26 #lcsm #oncology
Read more: www.onclive.com/view/extende...
Read more: www.onclive.com/view/extende...
📈 After progression on a third-generation EGFR TKI, izalontamab brengitecan (iza-bren) improved median PFS to 11.1 months vs 5.7 months with platinum-based chemotherapy in phase 3 PANKU-Lung01.
@myesmo.bsky.social #ESMO26 #lcsm #medtwitter #oncology
🔗 Read more: www.onclive.com/view/iza-bre...
@myesmo.bsky.social #ESMO26 #lcsm #medtwitter #oncology
🔗 Read more: www.onclive.com/view/iza-bre...
October 27, 2026 at 12:46 AM
📈 After progression on a third-generation EGFR TKI, izalontamab brengitecan (iza-bren) improved median PFS to 11.1 months vs 5.7 months with platinum-based chemotherapy in phase 3 PANKU-Lung01.
@myesmo.bsky.social #ESMO26 #lcsm #medtwitter #oncology
🔗 Read more: www.onclive.com/view/iza-bre...
@myesmo.bsky.social #ESMO26 #lcsm #medtwitter #oncology
🔗 Read more: www.onclive.com/view/iza-bre...
The cost of #lungcancer goes far beyond health. 💶
At #ESMO26, our President Debra Montague presented our poster showing 2 in 3 people affected by lung cancer face financial difficulties, & 82% of those struggling say money is a barrier to treatment & care.
📍 Poster 3975P
shorturl.at/ahecY #LCSM
At #ESMO26, our President Debra Montague presented our poster showing 2 in 3 people affected by lung cancer face financial difficulties, & 82% of those struggling say money is a barrier to treatment & care.
📍 Poster 3975P
shorturl.at/ahecY #LCSM
October 24, 2026 at 10:38 AM
The cost of #lungcancer goes far beyond health. 💶
At #ESMO26, our President Debra Montague presented our poster showing 2 in 3 people affected by lung cancer face financial difficulties, & 82% of those struggling say money is a barrier to treatment & care.
📍 Poster 3975P
shorturl.at/ahecY #LCSM
At #ESMO26, our President Debra Montague presented our poster showing 2 in 3 people affected by lung cancer face financial difficulties, & 82% of those struggling say money is a barrier to treatment & care.
📍 Poster 3975P
shorturl.at/ahecY #LCSM
📣 Presidential Symposium Spotlight 📣: Head-to-head vs sotorasib or adagrasib, divarasib improved PFS and OS in previously treated KRAS G12C+ NSCLC in the phase 3 Krascendo 1 trial.
Full @myesmo.bsky.social
#ESMO26 data: www.onclive.com/view/divaras...
#lcsm #oncology @mdanderson.bsky.social
Full @myesmo.bsky.social
#ESMO26 data: www.onclive.com/view/divaras...
#lcsm #oncology @mdanderson.bsky.social
October 25, 2026 at 8:02 PM
📣 Presidential Symposium Spotlight 📣: Head-to-head vs sotorasib or adagrasib, divarasib improved PFS and OS in previously treated KRAS G12C+ NSCLC in the phase 3 Krascendo 1 trial.
Full @myesmo.bsky.social
#ESMO26 data: www.onclive.com/view/divaras...
#lcsm #oncology @mdanderson.bsky.social
Full @myesmo.bsky.social
#ESMO26 data: www.onclive.com/view/divaras...
#lcsm #oncology @mdanderson.bsky.social
📣 A chemo-free option after osimertinib? In the phase 3 SAFFRON trial, osimertinib + savolitinib improved PFS and OS vs platinum/pemetrexed in EGFR+ NSCLC with MET overexpression/amplification.
Full @myesmo.bsky.social #ESMO26 data: www.onclive.com/view/saffron...
#oncology #lcsm
Full @myesmo.bsky.social #ESMO26 data: www.onclive.com/view/saffron...
#oncology #lcsm
October 25, 2026 at 7:06 PM
📣 A chemo-free option after osimertinib? In the phase 3 SAFFRON trial, osimertinib + savolitinib improved PFS and OS vs platinum/pemetrexed in EGFR+ NSCLC with MET overexpression/amplification.
Full @myesmo.bsky.social #ESMO26 data: www.onclive.com/view/saffron...
#oncology #lcsm
Full @myesmo.bsky.social #ESMO26 data: www.onclive.com/view/saffron...
#oncology #lcsm
TRIANA is on the programme at #ESMO2026 🔬
This Phase 1/2 trial in ALK+ #lungcancer tests TRI-611, a molecular glue designed to break down the ALK protein rather than block it.
Still early research, with no results yet. More at www.alkpositive.org.uk/information/...
Poster 2872 eTIP #LCSM
This Phase 1/2 trial in ALK+ #lungcancer tests TRI-611, a molecular glue designed to break down the ALK protein rather than block it.
Still early research, with no results yet. More at www.alkpositive.org.uk/information/...
Poster 2872 eTIP #LCSM
October 23, 2026 at 7:35 PM
TRIANA is on the programme at #ESMO2026 🔬
This Phase 1/2 trial in ALK+ #lungcancer tests TRI-611, a molecular glue designed to break down the ALK protein rather than block it.
Still early research, with no results yet. More at www.alkpositive.org.uk/information/...
Poster 2872 eTIP #LCSM
This Phase 1/2 trial in ALK+ #lungcancer tests TRI-611, a molecular glue designed to break down the ALK protein rather than block it.
Still early research, with no results yet. More at www.alkpositive.org.uk/information/...
Poster 2872 eTIP #LCSM
Leaked before #ESMO26: a personalised mRNA vaccine plus pembrolizumab lowered the risk of melanoma returning, or death, by 42%.
The same vaccine is in Phase 3 trials for early-stage #lungcancer, made from each person's tumour after surgery. Lung results are still to come.
shorturl.at/ND9zg #LCSM
The same vaccine is in Phase 3 trials for early-stage #lungcancer, made from each person's tumour after surgery. Lung results are still to come.
shorturl.at/ND9zg #LCSM
October 23, 2026 at 10:16 AM
Leaked before #ESMO26: a personalised mRNA vaccine plus pembrolizumab lowered the risk of melanoma returning, or death, by 42%.
The same vaccine is in Phase 3 trials for early-stage #lungcancer, made from each person's tumour after surgery. Lung results are still to come.
shorturl.at/ND9zg #LCSM
The same vaccine is in Phase 3 trials for early-stage #lungcancer, made from each person's tumour after surgery. Lung results are still to come.
shorturl.at/ND9zg #LCSM
A standing ovation: Tarlatamab + durvalumab as frontline maintenance in ES-SCLC, phase 3 DeLLphi-305.
Data presented at the @myesmo.bsky.social #ESMO26 Presidential Symposium support a new SOC. #lcsm #medtwitter #oncology @danafarber.bsky.social
www.onclive.com/view/dellphi...
Data presented at the @myesmo.bsky.social #ESMO26 Presidential Symposium support a new SOC. #lcsm #medtwitter #oncology @danafarber.bsky.social
www.onclive.com/view/dellphi...
DeLLphi-305 Data Support Frontline Maintenance Tarlatamab Plus Durvalumab as a New SOC in ES-SCLC | OncLive
Adding tarlatamab-dlle to durvalumab maintenance extended survival in extensive-stage small cell lung cancer in the phase 3 DeLLphi-305 trial.
www.onclive.com
October 24, 2026 at 8:10 PM
A standing ovation: Tarlatamab + durvalumab as frontline maintenance in ES-SCLC, phase 3 DeLLphi-305.
Data presented at the @myesmo.bsky.social #ESMO26 Presidential Symposium support a new SOC. #lcsm #medtwitter #oncology @danafarber.bsky.social
www.onclive.com/view/dellphi...
Data presented at the @myesmo.bsky.social #ESMO26 Presidential Symposium support a new SOC. #lcsm #medtwitter #oncology @danafarber.bsky.social
www.onclive.com/view/dellphi...
Poll Results: Readers share their opinions on some of the most talked-about lung cancer abstracts they’re looking forward to seeing at #ESMO2026. @myesmo.bsky.social #lcsm #oncology
Full recap ➡️: www.onclive.com/view/polls-r...
Full recap ➡️: www.onclive.com/view/polls-r...
Polls Reveal Top Picks for Lung Cancer Abstracts of Interest at ESMO 2026 | OncLive
Readers share their opinions on some of the most talked-about lung cancer abstracts they’re looking forward to seeing at ESMO 2026.
www.onclive.com
October 23, 2026 at 11:59 AM
Poll Results: Readers share their opinions on some of the most talked-about lung cancer abstracts they’re looking forward to seeing at #ESMO2026. @myesmo.bsky.social #lcsm #oncology
Full recap ➡️: www.onclive.com/view/polls-r...
Full recap ➡️: www.onclive.com/view/polls-r...
Lung Cancer Europe is in Madrid for #ESMO26. 🇪🇸
It's a big year for #lungcancer, with new trial results that could change treatment.
On Saturday, our President presents our research on the cost of lung cancer: 2 in 3 people we surveyed were struggling financially.
📍 3975P, Sat 24 Oct, 12:00
#LCSM
It's a big year for #lungcancer, with new trial results that could change treatment.
On Saturday, our President presents our research on the cost of lung cancer: 2 in 3 people we surveyed were struggling financially.
📍 3975P, Sat 24 Oct, 12:00
#LCSM
October 22, 2026 at 2:53 PM
Lung Cancer Europe is in Madrid for #ESMO26. 🇪🇸
It's a big year for #lungcancer, with new trial results that could change treatment.
On Saturday, our President presents our research on the cost of lung cancer: 2 in 3 people we surveyed were struggling financially.
📍 3975P, Sat 24 Oct, 12:00
#LCSM
It's a big year for #lungcancer, with new trial results that could change treatment.
On Saturday, our President presents our research on the cost of lung cancer: 2 in 3 people we surveyed were struggling financially.
📍 3975P, Sat 24 Oct, 12:00
#LCSM
Climate change could be raising #lungcancer risk inside our homes. 🌡️
As rising temps drive us into sealed, air-conditioned rooms & basements, radon builds up.
Modelling from a 🆕 study suggests up to 42 extra deaths per 10,000 people in Europe by age 85.
www.nature.com/articles/s44...
#LCSM
As rising temps drive us into sealed, air-conditioned rooms & basements, radon builds up.
Modelling from a 🆕 study suggests up to 42 extra deaths per 10,000 people in Europe by age 85.
www.nature.com/articles/s44...
#LCSM
October 21, 2026 at 8:01 PM
Climate change could be raising #lungcancer risk inside our homes. 🌡️
As rising temps drive us into sealed, air-conditioned rooms & basements, radon builds up.
Modelling from a 🆕 study suggests up to 42 extra deaths per 10,000 people in Europe by age 85.
www.nature.com/articles/s44...
#LCSM
As rising temps drive us into sealed, air-conditioned rooms & basements, radon builds up.
Modelling from a 🆕 study suggests up to 42 extra deaths per 10,000 people in Europe by age 85.
www.nature.com/articles/s44...
#LCSM
Could hotter summers increase #lungcancer deaths?
New research warns that changes to how we cool our homes could increase exposure to radon, a radioactive gas that causes lung cancer, including in people who have never smoked.
The risk is invisible. doi.org/10.1038/s444... #LCSM
New research warns that changes to how we cool our homes could increase exposure to radon, a radioactive gas that causes lung cancer, including in people who have never smoked.
The risk is invisible. doi.org/10.1038/s444... #LCSM
October 21, 2026 at 4:11 PM
Could hotter summers increase #lungcancer deaths?
New research warns that changes to how we cool our homes could increase exposure to radon, a radioactive gas that causes lung cancer, including in people who have never smoked.
The risk is invisible. doi.org/10.1038/s444... #LCSM
New research warns that changes to how we cool our homes could increase exposure to radon, a radioactive gas that causes lung cancer, including in people who have never smoked.
The risk is invisible. doi.org/10.1038/s444... #LCSM